LMA: IPO breathes life into Singapore's bioscience ambitions

An unusual healthcare IPO emerges out of Singapore.

Credit Suisse First Boston and DBS have begun pre-marketing a roughly $150 million IPO for medical devices company LMA Laryngeal Mask Airways. The deal is unusual because it has all the hallmarks of a Nasdaq IPO, but its founders have chosen to list in Singapore instead.

The company currently derives just under 60% of its sales from the US. Were it to list on Nasdaq, there would be a host of other medical...

To continue reading, please login or register for free

Click for more on: lma | ipo | breathes | life | singapores | bioscience | ambitions

Print Edition

FinanceAsia Print Edition

CONFERENCES